SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is a top trending stock following its recent earnings report, which showed stronger-than-expected results for the past quarter but included a weaker outlook for the current period due to supply constraints and manufacturing yields. This mixed news has sparked a fervent debate among investors, with many long-term bulls seeing a buying opportunity in the face of temporary challenges, citing the company's AI initiatives, advanced 18A node, and government backing for its foundry efforts. However, others remain cautious, pointing to the soft guidance as evidence of ongoing competitive struggles and concerns about the stock's valuation after its recent strong rally.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune Inc. is trending due to significant price action and volume, breaking key technical resistance levels, notably the $5 mark. The community is heavily speculating on a potential buyout or partnership, frequently mentioning major pharmaceutical players like Eli Lilly and Novo Nordisk, especially given its Breakthrough Therapy Designation for Pemvidutide. Discussions also highlight a potential short squeeze and the perceived undervaluation of the company's MASH/GLP-1 asset.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is generating significant buzz across trading communities, primarily driven by strong short-squeeze potential attributed to its exceptionally low public float and escalating buying interest. Traders are actively discussing the ongoing strategic review and the company's substantial cash position as key factors that could ignite a significant upward movement.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as the community eagerly anticipates its upcoming earnings report on February 3rd. The absence of a pre-earnings business update, unlike prior quarters, is widely seen as a bullish indicator, fueling speculation about a potential beat and igniting calls for a short squeeze. Despite lingering gross margin discussions and recent analyst downgrades, investors are focused on SMCI's critical role and perceived undervaluation in the rapidly expanding AI infrastructure market.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano (MOVE) is experiencing significant speculative interest following its merger announcement with Corvex, an AI cloud computing firm. The catalyst is Corvex's newly secured long-term NVIDIA H200 GPU deployment, fueling community discussion around a potential short squeeze given MOVE's notably low share float. While many anticipate substantial upward movement from the AI and NVIDIA association, others are exercising caution regarding the merger's valuation specifics and potential for volatility.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares are trending as Goldman Sachs recently raised its price target for gold, fueling bullish sentiment. The community is actively debating whether ongoing geopolitical tensions and concerns over fiat currency debasement will drive further record highs or if current overbought conditions signal an impending correction for the popular safe-haven asset.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amid positive developments surrounding its ANKTIVA cancer treatment, including advancements in regulatory resubmission discussions and international approvals. The community is intensely focused on the stock's remarkable streak of consecutive green days and a perceived short squeeze, fueled by high borrowing costs for short sellers and strong belief in the company's long-term potential in cancer therapy.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending on news of strategic partnerships and ambitious 2026 goals, highlighting its specialized flexible solar technology for the burgeoning space and defense industries. Community discussion is amplified by connections to Elon Musk's recent comments on solar-powered AI satellites and the presence of a former SpaceX founder on ASTI's board, fueling speculation about significant upside potential and short squeeze plays despite past dilution concerns.

Capital One Financial Corp. is a financial holding company, which engages in the provision of financial products and services. It operates through the following segments: Credit Card, Consumer Banking, and Commercial Banking. The Credit Card segment includes domestic consumer and small business card lending, and international card lending businesses. The Consumer Banking segment consists of branch-based lending and deposit gathering activities for consumers and small businesses. The Commercial Banking segment includes lending, deposit gathering and treasury management services to commercial real estate and commercial and industrial customers. The company was founded by Richard D. Fairbank on July 21, 1994 and is headquartered in McLean, VA.

Capital One Financial Corp.

Capital One is trending due to the finalization of its major acquisition of Discover Financial Services and the concurrent announcement of its Brex acquisition, moves poised to reshape its position in the credit card and fintech sectors. These strategic developments are fueling diverse community discussion, further intensified by mixed quarterly earnings results and a widely debated proposal for a credit card interest rate cap, collectively driving varied investor sentiment amid regulatory scrutiny.

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals (SXTP) is actively trending following its new partnership with Runway Health, which aims to provide broader access to its FDA-approved malaria prevention drug, ARAKODA, via a telehealth platform. This development, coupled with its recently reduced share float from a reverse split, has ignited intense community discussion, with traders anticipating potential for a multi-day run or short squeeze amidst cautionary talk of dilution and historical pump-and-dump patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>UBS’ new price target represents a potential upside of about 55% from the stock’s closing price on Thursday.&nbsp;</li><li>UBS sees higher energy storage demand and years of slower western capacity additions pushing the lithium markets into deficit in 2026.</li><li>Lithium prices should move up through the year, which should be a positive driver for Albemarle shares, the analyst said.</li></ul>Shares of Lithium producer Albemarle (ALB) traded 6% higher on Friday afternoon after UBS highlighted a possible Lithium supply deficit next year.The firm upgraded Albemarle to ‘Buy’ from ‘Neutral’ with a price target of $185, up from $107.The new price target represents a potential upside of about 55% from the stock’s closing price on Thursday.<h2 class="st-heading-2">UBS’ Rationale</h2>UBS sees higher energy storage demand and years of slower western capacity additions pushing the lithium markets into deficit in 2026. Lithium prices should move up through the year, which should be a positive driver for Albemarle shares, the analyst told investors in a research note. UBS now sees a lithium supply deficit in the second half of 2026.Lithium prices have been aided by an increase in demand from the rise of electric vehicles and large-scale battery storage. Lithium spot prices are now more than 50% above a June low.During the company’s earnings call in November, CEO Kent Masters said that overall demand for lithium remains “robust.”“Overall demand for lithium remains robust, up more than 30% year-to-date, supported by the energy transition and rising global demand for electric vehicles and grid storage,” the CEO said.According to data from Koyfin, 18 of 26 analysts covering Albemarle have a ‘Hold’ rating on the stock. While seven analysts rate the stock ‘Buy’ or higher, one rates it a ‘Sell.’ The average price target on the stock is at $108.14, representing potential downside from Thursday’s close.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALB stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/ALB">ALB stock</a> is up by 47% this year and by about 25% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/compass-diversified-stock-plunges-on-most-significant-loss-after-fraud-forces-removal-of-three-years-of-financials/cLISaAoREkA">Compass Diversified Stock Plunges On ‘Most Significant Loss’ After Fraud Forces Removal Of Three Years Of Financials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, a smartphone displays the logo of Albemarle Corporation (NYSE: ALB). 

Why Is Albemarle Stock Up 6% Today?

UBS upgraded Albemarle to ‘Buy’ from ‘Neutral’ with a price target of $185, up from $107. 

Equity

UBS upgraded Albemarle to ‘Buy’ from ‘Neutral’ with a price target of $185, up from $107. 


Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

GMET
VanEck Green Metals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GMET News

GMETVanEck Green Metals ETF